These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
6. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971 [TBL] [Abstract][Full Text] [Related]
7. Cladribine Tablets: A Review in Relapsing MS. Deeks ED CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527 [TBL] [Abstract][Full Text] [Related]
8. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study. Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393 [TBL] [Abstract][Full Text] [Related]
10. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic. Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356 [TBL] [Abstract][Full Text] [Related]
11. Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine. Biernacki T; Sandi D; Bencsik K; Vécsei L Mini Rev Med Chem; 2020; 20(4):269-285. PubMed ID: 31644403 [TBL] [Abstract][Full Text] [Related]
12. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476 [TBL] [Abstract][Full Text] [Related]
13. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743 [TBL] [Abstract][Full Text] [Related]
14. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study. Rolfes L; Pfeuffer S; Huntemann N; Schmidt M; Su C; Skuljec J; Aslan D; Hackert J; Kleinschnitz K; Hagenacker T; Pawlitzki M; Ruck T; Kleinschnitz C; Meuth SG; Pul R Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010 [TBL] [Abstract][Full Text] [Related]
15. Development of oral cladribine for the treatment of multiple sclerosis. Hartung HP; Aktas O; Kieseier B; Giancarlo Comi GC J Neurol; 2010 Feb; 257(2):163-70. PubMed ID: 19921304 [TBL] [Abstract][Full Text] [Related]
16. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375 [TBL] [Abstract][Full Text] [Related]
17. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis. Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133 [TBL] [Abstract][Full Text] [Related]